McKesson Corporation $MCK Stock Position Lifted by PensionDanmark Pensionsforsikringsaktieselskab

PensionDanmark Pensionsforsikringsaktieselskab lifted its position in McKesson Corporation (NYSE:MCK) by 8.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,850 shares of the company’s stock after acquiring an additional 2,525 shares during the quarter. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in McKesson were worth $23,310,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. University of Texas Texas AM Investment Management Co. acquired a new position in McKesson in the fourth quarter worth $25,000. Swiss RE Ltd. bought a new stake in McKesson during the fourth quarter valued at $26,000. State of Wyoming acquired a new stake in shares of McKesson during the second quarter worth $29,000. Kingdom Financial Group LLC. acquired a new stake in shares of McKesson during the fourth quarter worth $33,000. Finally, Birchwood Financial Partners Inc. bought a new position in shares of McKesson in the 4th quarter worth about $33,000. 85.07% of the stock is currently owned by institutional investors.

More McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson reported adjusted earnings of $9.93 per share, above the $9.56 consensus estimate, while revenue rose 7.7% year over year to $105.38 billion, exceeding expectations of $103.88 billion. Earnings also increased from $8.26 per share in the prior-year quarter. McKesson Fiscal Q1 Earnings Report
• Positive Sentiment: The company raised fiscal 2027 adjusted EPS guidance to $44.20-$45.00, broadly above the prior outlook and near or above analyst expectations. Revenue guidance was set at approximately $423.6 billion-$439.7 billion. McKesson Raises Full-Year EPS Guidance
• Positive Sentiment: Pharmaceutical profit grew 19%, led by specialty medicine demand and oncology growth. Management also highlighted disciplined spending, supporting the improved earnings outlook. MCK Q1 Earnings Call Centers on Pharma-Led Guidance Raise
• Positive Sentiment: McKesson plans to repurchase up to $5 billion of shares and reportedly raised its dividend by 15%, providing additional potential shareholder returns. McKesson Fiscal 2027 EPS and Share Repurchase Plan
• Neutral Sentiment: McKesson’s Medical-Surgical Solutions business is being rebranded as Wellverse ahead of a planned spin-off and IPO. The move could unlock value, but its financial impact and timing remain uncertain. McKesson Medical-Surgical Rebrands as Wellverse

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. TD Cowen lifted their price target on shares of McKesson from $989.00 to $1,006.00 and gave the company a “buy” rating in a report on Thursday. William Blair began coverage on shares of McKesson in a report on Tuesday, April 28th. They issued an “outperform” rating on the stock. Barclays cut their target price on shares of McKesson from $1,050.00 to $925.00 and set an “overweight” rating on the stock in a report on Wednesday, June 10th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $875.00 target price on shares of McKesson in a report on Friday, May 8th. Finally, JPMorgan Chase & Co. cut their price target on McKesson from $1,107.00 to $1,015.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Fourteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $968.93.

McKesson Trading Down 0.5%

Shares of NYSE:MCK opened at $872.68 on Friday. The company has a 50 day moving average of $798.08 and a 200-day moving average of $840.76. The firm has a market cap of $102.17 billion, a P/E ratio of 23.35, a P/E/G ratio of 1.44 and a beta of 0.30. McKesson Corporation has a twelve month low of $637.00 and a twelve month high of $999.00.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $9.93 EPS for the quarter, beating analysts’ consensus estimates of $9.56 by $0.37. McKesson had a net margin of 1.12% and a negative return on equity of 371.86%. The business had revenue of $105.38 billion for the quarter, compared to analyst estimates of $103.88 billion. During the same quarter last year, the business earned $8.26 earnings per share. The business’s revenue for the quarter was up 7.7% on a year-over-year basis. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. Equities research analysts forecast that McKesson Corporation will post 44.28 EPS for the current year.

McKesson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 1st. Shareholders of record on Tuesday, September 1st will be paid a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Tuesday, September 1st. This is an increase from McKesson’s previous quarterly dividend of $0.82. McKesson’s dividend payout ratio is 8.53%.

Insider Transactions at McKesson

In related news, CEO Brian S. Tyler sold 8,463 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $793.56, for a total transaction of $6,715,898.28. Following the completion of the transaction, the chief executive officer owned 5,919 shares of the company’s stock, valued at $4,697,081.64. This trade represents a 58.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Napoleon B. Rutledge, Jr. sold 133 shares of McKesson stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $764.00, for a total value of $101,612.00. Following the transaction, the chief accounting officer directly owned 632 shares in the company, valued at approximately $482,848. The trade was a 17.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 28,748 shares of company stock valued at $22,262,035 in the last quarter. Company insiders own 0.06% of the company’s stock.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.